close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.170 +0.280 (+4.75%)
Official Closing Price Updated: 8:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing
Via Investor Brand Network
News headline image
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
From Cybin Inc.
Via Business Wire
News headline image
Analyst Expectations for Cybin's Future ↗
 
Via Benzinga
News headline image
Expedia To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event
Via Investor Brand Network
News headline image
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
From Cybin Inc.
Via Business Wire
News headline image
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals ↗
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
From Cybin Inc.
Via Business Wire
News headline image
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
News headline image
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? 
Via Benzinga
Topics Initial Public Offering
News headline image
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal ↗
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
Via Investor Brand Network
News headline image
Cybin Announces up to US$64 Million Offering of Units
From Cybin Inc.
Via Business Wire
News headline image
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court 
Via Benzinga
Topics Economy
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
Via Investor Brand Network
News headline image
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
News headline image
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find ↗
Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003 
Via Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
Via Investor Brand Network
News headline image
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
From Cybin Inc.
Via Business Wire
News headline image
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property
News headline image
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents ↗
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) 
Via Benzinga
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
From Cybin Inc.
Via Business Wire
News headline image
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics ↗
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today